Medical News

RSS

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

OSI Pharmaceuticals, Inc. announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva (erlotinib) as an adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer who have undergone surgery and have EGFR-positive tumors.

26 Apr 2010

American board-certified prosthetist develops custom-made ankle-foot orthosis

With over ten million diabetics in the U.S. alone and approximately 150,000 amputations performed yearly, inventor and American board-certified prosthetist John E. Rooney developed a custom-made ankle-foot orthosis with the trade name Ulcer Healing Orthosis or UHO.

26 Apr 2010

CompCare launches behavioral health services for a health plan in Texas

Comprehensive Care Corporation today announced the launching of its behavioral health services for a health plan in Texas.

26 Apr 2010

Novartis exercises current right to purchase 55,223 unregistered shares of Alnylam's common stock

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that Novartis has elected to fully exercise its current right to purchase 55,223 unregistered shares of Alnylam's common stock in accordance with the terms of the Investor Rights Agreement between Alnylam and Novartis, dated September 6, 2005.

26 Apr 2010

First patient enrolled in Phase II clinical trial of E10030 for treatment of wet age-related AMD

Ophthotech Corp., a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, today announced that the first patient has been enrolled in its Phase II randomized, controlled clinical trial of E10030, an anti-PDGF aptamer, in combination with Lucentis® for the treatment of wet age-related macular degeneration (AMD).

26 Apr 2010

New FDA approved Landon Medical PC-60C2 Finger Pulse Oximeter introduced for home use

PulseOximetersDIRECT.com, the leading online retailer of portable Pulse Oximeter products introduces today the new FDA approved Landon Medical PC-60C2 Finger Pulse Oximeter for home use.

26 Apr 2010

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced today that the National Cancer Institute has initiated a Phase 1/2 clinical trial of TRC105 therapy for patients with castrate-resistant prostate cancer.

26 Apr 2010

Cytovance Biologics, Selexys Pharmaceutical announce collaboration for Anti-PSGL-1 therapeutic agent

Cytovance Biologics, LLC and Selexys Pharmaceutical Corporation jointly announce an agreement and execution of a Biopharmaceutical Development and Manufacturing collaboration for their Anti-PSGL-1 therapeutic agent. This monoclonal antibody (mAb) is being developed for treatment of inflammation associated with Crohn's disease as a lead indication.

26 Apr 2010

Duke University Medical Center installs Veran Medical Technologies' SPiN Drive system

Veran Medical Technologies announced today that it has recently completed its first installation and performed several procedures at Duke University Medical Center with its FDA-cleared SPiN Drive product. The product enables clinicians to navigate deep into the peripheral regions of the lungs to access, biopsy and treat potentially cancerous Solitary Pulmonary Nodules.

26 Apr 2010

BG Medicine, Inverness Medical Innovations enter agreement for galectin-3 test for Triage Meter Pro

BG Medicine, Inc. announced today that it has entered into an agreement with Inverness Medical Innovations, Inc.—a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management—for the development and commercialization of a galectin-3 test for Inverness' Triage® Meter Pro®. Galectin-3 is a novel biomarker that may play a role in detecting the development and progression of heart failure.

26 Apr 2010

Bayer Diabetes Care launches DIDGET blood glucose monitoring system in the US

Bayer Diabetes Care today announced the introduction of the DIDGET™ blood glucose monitoring system in the United States. The DIDGET meter is unique because it is the only blood glucose meter that connects directly to Nintendo DS™ and DS Lite gaming systems to help kids manage a lifelong disease by rewarding them for building consistent testing habits and meeting personalized blood glucose target ranges. Bayer's DIDGET meter is now available for purchase in the U.S. through CVS.com, Drugstore.com and Walgreens.com.

26 Apr 2010

Thoratec to sell ITC division to Danaher

Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it has signed a definitive agreement to sell its International Technidyne Corporation (ITC) division to Danaher Corporation ( DHR).

From Danaher 26 Apr 2010

Grape-enriched diet prevents risk factors for metabolic syndrome: Researchers

Scientists at the University of Michigan Health System are teasing out clues to the effect of grapes in reducing risk factors related to cardiovascular disease and metabolic syndrome. The effect is thought to be due to phytochemicals -- naturally occurring antioxidants - that grapes contain.

26 Apr 2010

Life Technologies debuts Invitrogen MAGic Sample Processor for addressing reproducibility challenges

Life Technologies Corporation today debuted the life science industry's first benchtop sample preparation system designed to increase productivity while eliminating manual and contamination-related challenges traditionally associated with protein and epigenetic protocols. The Invitrogen MAGic™ Sample Processor enables researchers to cut protocol time in half, dramatically reduce experimental errors, and perform technically challenging experiments in protein purification and epigenetics.

26 Apr 2010

Avecia Biotechnology reaches agreement with Pfizer to market Macugen

Avecia Biotechnology, Inc., a leading provider of drug development and manufacturing services for oligonucleotide therapeutics, has reached agreement with Pfizer Inc. regarding the commercial supply of a key component of Macugen (pegaptanib sodium injection), marketed in the E.U. by Pfizer for the treatment of wet Age-Related Macular Degeneration.

26 Apr 2010

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.

26 Apr 2010

OICR makes equity investments in three promising Ontario technologies

Frank Stonebanks, Vice-President, Commercialization and Chief Commercial Officer of the Ontario Institute for Cancer Research today announced that OICR has made equity investments in three promising Ontario technologies to accelerate their commercialization.

26 Apr 2010

National Securities, MD Becker Partners to host SCIENCE program

National Securities Corporation and MD Becker Partners will host their inaugural Stem Cell Investor & Executive Networking Conference Event on June 1, 2010, from 11:00am to 3:00pm (EDT), at National Securities Corporation Global Headquarters at 120 Broadway, (2nd Floor Conference Center) in New York City.

26 Apr 2010

Bruker to supply customized N8 TITANOS large sample AFM to US Commerce Department's NIST

Bruker today announced that it has been awarded a $1.1 million contract to supply a customized N8 TITANOS™ large sample Atomic Force Microscope (AFM) to the United States Commerce Department's National Institute of Standards and Technology (NIST). The instrument will be used by NIST's Precision Engineering Division (PED) at its Manufacturing Engineering Laboratory, with a main focus on metrology applications which require traceable AFM (T-AFM).

26 Apr 2010

Nanoviricides become registered trademark under USPTO

NanoViricides, Inc., announced today that the mark "nanoviricides" has now become a registered trademark under the US Patents and Trademarks Office. The mark was entered into the "principal register" of trademarks at the USPTO on April 20, 2010.

26 Apr 2010

Medical News

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

American board-certified prosthetist develops custom-made ankle-foot orthosis

CompCare launches behavioral health services for a health plan in Texas

Novartis exercises current right to purchase 55,223 unregistered shares of Alnylam's common stock

First patient enrolled in Phase II clinical trial of E10030 for treatment of wet age-related AMD

New FDA approved Landon Medical PC-60C2 Finger Pulse Oximeter introduced for home use

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

Cytovance Biologics, Selexys Pharmaceutical announce collaboration for Anti-PSGL-1 therapeutic agent

Duke University Medical Center installs Veran Medical Technologies' SPiN Drive system

BG Medicine, Inverness Medical Innovations enter agreement for galectin-3 test for Triage Meter Pro

Bayer Diabetes Care launches DIDGET blood glucose monitoring system in the US

Thoratec to sell ITC division to Danaher

Grape-enriched diet prevents risk factors for metabolic syndrome: Researchers

Life Technologies debuts Invitrogen MAGic Sample Processor for addressing reproducibility challenges

Avecia Biotechnology reaches agreement with Pfizer to market Macugen

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

OICR makes equity investments in three promising Ontario technologies

National Securities, MD Becker Partners to host SCIENCE program

Bruker to supply customized N8 TITANOS large sample AFM to US Commerce Department's NIST

Nanoviricides become registered trademark under USPTO

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News